SCHEMBL6779878

SCHEMBL6779878

Cc1ccsc1C(CC(=O)O)NC(=O)CNC(=O)c1cccc(NC(=N)N)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 15/20 0.47
ITGAV P06756 12/20 0.47
ITGB1 P05556 7/20 0.47
ITGA5 P08648 7/20 0.47
ITGB6 P18564 7/20 0.47
ITGB5 P18084 3/20 0.47
ITGB8 P26012 3/20 0.47
ITGA8 P53708 3/20 0.47
MDM2 Q00987 3/20 0.41
MDM4 O15151 3/20 0.41
ITGA2B P08514 3/20 0.40
GPR139 Q6DWJ6 1/20 0.40
F2 P00734 1/20 0.39
F7 P08709 1/20 0.39
PARP1 P09874 1/20 0.38
PARP10 Q53GL7 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7833746 0.88 ITGB3 (0.50) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6778844 0.88 PTPRC (0.37) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6779887 0.86 ITGB3 (0.46) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6777371 0.85 ITGB3 (0.44) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6778768 0.84 ITGB3 (0.60) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6773834 0.84 ITGB3 (0.51) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL242674 0.84 ITGB3 (0.55) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6777666 0.84 ITGB3 (0.47) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6776064 0.83 ITGB3 (0.46) ITGB3ITGAVITGB1ITGA5ITGB6
SCHEMBL6778330 0.82 ITGB3 (0.44) ITGB3ITGAVITGB1ITGA5ITGB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed